ERBP Documents per topic

ERBP GUIDELINES PHILOSOPHY

The future of European Nephrology ‘Guidelines’—a declaration of intent by European Renal Best Practice (ERBP) - NDT Plus

European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP)

ACUTE KIDNEY INJURY

Full Guideline (English): Crush recommendations: a step forward in disaster nephrology (official ERBP Publication)
Full Guideline (Turkish) : Crush recommendations: a step forward in disaster nephrology
Full Guideline (Chinese): Crush recommendations: a step forward in disaster nephrology
(disclaimer: Care has been taken to assure a correct translation of the original ERBP Guideline publication -ERBP cannot be held liable for any mistakes/mistranslations that may have occurred during translation)

Short Field Version (English): Crush recommendation a step forward in disaster nephrology
Short Field Version (Italian): Crush recommendation a step forward in disaster nephrology
Short Field Version (Spanish): Crush recommendation a step forward in disaster nephrology
(disclaimer: Care has been taken to assure a correct translation of the original ERBP Guideline publication -ERBP cannot be held liable for any mistakes/mistranslations that may have occurred during translation)

A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy

CLINICAL NEPHROLOGY

Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults

Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease

Guideline on Management of Older Patients with Chronic Kidney Disease
Field version available in 22 languages

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Important update (2019): please note that this document was published in January 2016 and considered the Tempo 3:4 Trial and former EMA licence regarding Tolvaptan. Since then, the Tempo 4:4 results have been published, there has been a new trial (REPRISE) and an update of the EMA licence, which means that this ERBP document is outdated. ERBP cannot confirm at this time whether an update will follow.

Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min)
Field version available in 18 languages

Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement.

Clinical practice guideline on diagnosis and treatment of hyponatraemia
Field versions available in 18 languages

Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?

Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study

Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)

HAEMODIALYSIS

Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP) - NDT Plus

Educating end-stage renal disease patients on dialysis modality selection - NDT Plus

High-flux or low-flux dialysis: A position statement following publication of the Membrane Permeability Outcome (MPO) study